Gastric cancer (GC) is the sixth most common malignancy and the third leading cause of cancer-related death worldwide. 1 Despite the declining morbidity as well as mortality and the significant advances in the comprehension of aetiology and molecular mechanisms, the burden remains high in Asia, Latin America, and eastern and central part of Europe. 2 Although several treatment approaches are applied including surgery, chemotherapy, radiation therapy and molecular targeted therapies, the long-term outcome of GC patients at advanced stages remains disappointing. 3,4 The tumour microenvironment (TME) refers to the environment in which cancer cells originate and develop. Except for cancer cells, the TME consists of different cell types (stromal cells, immune cells, endothelial cells, etc) and extracellular elements (chemokine, cytokines, hormones, etc). 5,6 Emerging evidence suggests that TME cells (including macrophages, T cells and fibroblasts) all play a vital role in the initiation and progression of GC. 7-11 As two major cell types apart from cancer cells in the TME, stromal cells and immune cells exhibit important role in diagnostic and prognostic evaluation of solid tumours. Stromal cells can receive signals sent by cancer cells and then supply the cancer cells with a variety of growth factors, which are essential for invasive growth and metastasis. 12-17 On the other hand, the immune cells in the TME function in a context-dependent way: tumour-antagonizing effects of T cells in ovarian cancer 18-20 and tumour-promoting effects in colorectal cancer. 21,22 Hence, an overall understanding of stromal cells and immune cells